Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer.

Article Type
Changed
Display Headline
Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer
A perspective on the women's health study
Article PDF
Author and Disclosure Information

Julie E. Burning, ScD
Professor of Medicine, Harvard Medical School; Division of Preventive Medicine, Brigham and Women’s Hospital, Boston; principal investigator, Women’s Health Study

Address: Julie E. Buring, ScD, Division of Preventive Medicine, Brigham and Women’s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215; e-mail [email protected]

Dr. Buring has received investigator-initiated research funding and support as Principal Investigator from the National Institutes of Health (the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Aging) and Dow Corning Corporation; has received research support for pills and/or packaging from Bayer Health Care and the Natural Source Vitamin E Association; has received honoraria from Bayer for speaking engagements; and has served on a study’s external scientific advisory committee for Procter & Gamble.

This Medical Grand Rounds article is based on edited transcripts from a Heart Center Grand Rounds presentation at Cleveland Clinic. It was approved by the author but was not peer-reviewed.

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
863-870
Sections
Author and Disclosure Information

Julie E. Burning, ScD
Professor of Medicine, Harvard Medical School; Division of Preventive Medicine, Brigham and Women’s Hospital, Boston; principal investigator, Women’s Health Study

Address: Julie E. Buring, ScD, Division of Preventive Medicine, Brigham and Women’s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215; e-mail [email protected]

Dr. Buring has received investigator-initiated research funding and support as Principal Investigator from the National Institutes of Health (the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Aging) and Dow Corning Corporation; has received research support for pills and/or packaging from Bayer Health Care and the Natural Source Vitamin E Association; has received honoraria from Bayer for speaking engagements; and has served on a study’s external scientific advisory committee for Procter & Gamble.

This Medical Grand Rounds article is based on edited transcripts from a Heart Center Grand Rounds presentation at Cleveland Clinic. It was approved by the author but was not peer-reviewed.

Author and Disclosure Information

Julie E. Burning, ScD
Professor of Medicine, Harvard Medical School; Division of Preventive Medicine, Brigham and Women’s Hospital, Boston; principal investigator, Women’s Health Study

Address: Julie E. Buring, ScD, Division of Preventive Medicine, Brigham and Women’s Hospital, 900 Commonwealth Avenue East, Boston, MA 02215; e-mail [email protected]

Dr. Buring has received investigator-initiated research funding and support as Principal Investigator from the National Institutes of Health (the National Heart, Lung, and Blood Institute, the National Cancer Institute, and the National Institute of Aging) and Dow Corning Corporation; has received research support for pills and/or packaging from Bayer Health Care and the Natural Source Vitamin E Association; has received honoraria from Bayer for speaking engagements; and has served on a study’s external scientific advisory committee for Procter & Gamble.

This Medical Grand Rounds article is based on edited transcripts from a Heart Center Grand Rounds presentation at Cleveland Clinic. It was approved by the author but was not peer-reviewed.

Article PDF
Article PDF
A perspective on the women's health study
A perspective on the women's health study
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
863-870
Page Number
863-870
Publications
Publications
Topics
Article Type
Display Headline
Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer
Display Headline
Aspirin prevents stroke but not MI in women; vitamin E has no effect on CV disease or cancer
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Imaging's roles in acute pancreatitis

Article Type
Changed
Display Headline
Imaging's roles in acute pancreatitis
Article PDF
Author and Disclosure Information

Tina Bolek, MD
Department of Diagnostic Radiology, Cleveland Clinic

Mark E. Baker, MD
Department of Diagnostic Radiology, Cleveland Clinic

R. Matthew Walsh, MD
Department of General Surgery, Cleveland Clinic

Address: Mark E. Baker, Department of Diagnostic Radiology, Hb6, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
857-862
Sections
Author and Disclosure Information

Tina Bolek, MD
Department of Diagnostic Radiology, Cleveland Clinic

Mark E. Baker, MD
Department of Diagnostic Radiology, Cleveland Clinic

R. Matthew Walsh, MD
Department of General Surgery, Cleveland Clinic

Address: Mark E. Baker, Department of Diagnostic Radiology, Hb6, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Author and Disclosure Information

Tina Bolek, MD
Department of Diagnostic Radiology, Cleveland Clinic

Mark E. Baker, MD
Department of Diagnostic Radiology, Cleveland Clinic

R. Matthew Walsh, MD
Department of General Surgery, Cleveland Clinic

Address: Mark E. Baker, Department of Diagnostic Radiology, Hb6, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; [email protected]

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
857-862
Page Number
857-862
Publications
Publications
Topics
Article Type
Display Headline
Imaging's roles in acute pancreatitis
Display Headline
Imaging's roles in acute pancreatitis
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Newer antibiotics for serious gram-positive infections

Article Type
Changed
Display Headline
Newer antibiotics for serious gram-positive infections
Article PDF
Author and Disclosure Information

Thomas G. Fraser, MD
Department of Infectious Diseases, Cleveland Clinic

Christine Hansen, PharmD
Department of Pharmacy, Shands Hospital, Orlando, FL

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Address: Thomas G. Fraser, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Fraser is a member of the Wyeth Emerging Pathogens speakers’ bureau.

Dr. Long is a member of the Cubist speakers’ bureau and the Pfizer speakers’ bureau. This manuscript was generated without outside funding.

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
847-853
Sections
Author and Disclosure Information

Thomas G. Fraser, MD
Department of Infectious Diseases, Cleveland Clinic

Christine Hansen, PharmD
Department of Pharmacy, Shands Hospital, Orlando, FL

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Address: Thomas G. Fraser, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Fraser is a member of the Wyeth Emerging Pathogens speakers’ bureau.

Dr. Long is a member of the Cubist speakers’ bureau and the Pfizer speakers’ bureau. This manuscript was generated without outside funding.

Author and Disclosure Information

Thomas G. Fraser, MD
Department of Infectious Diseases, Cleveland Clinic

Christine Hansen, PharmD
Department of Pharmacy, Shands Hospital, Orlando, FL

Jennifer K. Long, PharmD
Department of Pharmacy, Cleveland Clinic

Address: Thomas G. Fraser, MD, Department of Infectious Disease, S32, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Fraser is a member of the Wyeth Emerging Pathogens speakers’ bureau.

Dr. Long is a member of the Cubist speakers’ bureau and the Pfizer speakers’ bureau. This manuscript was generated without outside funding.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
847-853
Page Number
847-853
Publications
Publications
Topics
Article Type
Display Headline
Newer antibiotics for serious gram-positive infections
Display Headline
Newer antibiotics for serious gram-positive infections
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Tending to the musculoskeletal problems of obesity

Article Type
Changed
Display Headline
Tending to the musculoskeletal problems of obesity
Article PDF
Author and Disclosure Information

Michele M. Hooper, MD, MS
Associate director of medical affairs, Amgen Inc, Thousand Oaks, CA

Address: Michele M. Hooper, MD, Amgen, One Amgen Center Drive, MS 27-1-D, Thousand Oaks, CA 91320; e-mail [email protected]

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
839-845
Sections
Author and Disclosure Information

Michele M. Hooper, MD, MS
Associate director of medical affairs, Amgen Inc, Thousand Oaks, CA

Address: Michele M. Hooper, MD, Amgen, One Amgen Center Drive, MS 27-1-D, Thousand Oaks, CA 91320; e-mail [email protected]

Author and Disclosure Information

Michele M. Hooper, MD, MS
Associate director of medical affairs, Amgen Inc, Thousand Oaks, CA

Address: Michele M. Hooper, MD, Amgen, One Amgen Center Drive, MS 27-1-D, Thousand Oaks, CA 91320; e-mail [email protected]

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
839-845
Page Number
839-845
Publications
Publications
Topics
Article Type
Display Headline
Tending to the musculoskeletal problems of obesity
Display Headline
Tending to the musculoskeletal problems of obesity
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Is digoxin a drug of the past?

Article Type
Changed
Display Headline
Is digoxin a drug of the past?
Article PDF
Author and Disclosure Information

Mohammad Hassan Pervaiz, MD
Department of Medicine, Michigan State University, East Lansing

Michael G. Dickinson, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Mohamad Yamani, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: Mohammad Hassan Pervaiz, MD, B-301 Clinical Center, Michigan State University, East Lansing, MI 44824; email [email protected]

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
821-824, 826, 829-832, 834, 838
Sections
Author and Disclosure Information

Mohammad Hassan Pervaiz, MD
Department of Medicine, Michigan State University, East Lansing

Michael G. Dickinson, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Mohamad Yamani, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: Mohammad Hassan Pervaiz, MD, B-301 Clinical Center, Michigan State University, East Lansing, MI 44824; email [email protected]

Author and Disclosure Information

Mohammad Hassan Pervaiz, MD
Department of Medicine, Michigan State University, East Lansing

Michael G. Dickinson, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Mohamad Yamani, MD
Department of Cardiovascular Medicine, Cleveland Clinic

Address: Mohammad Hassan Pervaiz, MD, B-301 Clinical Center, Michigan State University, East Lansing, MI 44824; email [email protected]

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
821-824, 826, 829-832, 834, 838
Page Number
821-824, 826, 829-832, 834, 838
Publications
Publications
Topics
Article Type
Display Headline
Is digoxin a drug of the past?
Display Headline
Is digoxin a drug of the past?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Migraine prophylaxis: Who, why, and how

Article Type
Changed
Display Headline
Migraine prophylaxis: Who, why, and how
Article PDF
Author and Disclosure Information

Jadwiga Loj, MD
Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL

Glen D. Solomon, MD
Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL

Address: Glen D. Solomon, MD, Department of Medicine, Advocate Lutheran General Hospital, 1775 Dempster Street, Park Ridge, IL 60068; e-mail [email protected]

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
793-794, 797, 800-801, 806, 808, 810, 813-814, 816
Sections
Author and Disclosure Information

Jadwiga Loj, MD
Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL

Glen D. Solomon, MD
Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL

Address: Glen D. Solomon, MD, Department of Medicine, Advocate Lutheran General Hospital, 1775 Dempster Street, Park Ridge, IL 60068; e-mail [email protected]

Author and Disclosure Information

Jadwiga Loj, MD
Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL

Glen D. Solomon, MD
Department of Medicine, Advocate Lutheran General Hospital, Park Ridge, IL

Address: Glen D. Solomon, MD, Department of Medicine, Advocate Lutheran General Hospital, 1775 Dempster Street, Park Ridge, IL 60068; e-mail [email protected]

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
793-794, 797, 800-801, 806, 808, 810, 813-814, 816
Page Number
793-794, 797, 800-801, 806, 808, 810, 813-814, 816
Publications
Publications
Topics
Article Type
Display Headline
Migraine prophylaxis: Who, why, and how
Display Headline
Migraine prophylaxis: Who, why, and how
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

When should prophylactic anticoagulation begin after a hip fracture?

Article Type
Changed
Display Headline
When should prophylactic anticoagulation begin after a hip fracture?
Article PDF
Author and Disclosure Information

Paul J. Grant, MD
Clinical instructor, Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

Amir K. Jaffer, MD
Medical director, IMPACT (Internal Medicine Preoperative Assessment Consultation and Treatment) Center; medical director, Anticoagulation Clinic, Section of Hospital Medicine, Cleveland Clinic

Address: Amir K. Jaffer, MD, IMPACT Center, A13, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Jaffer has indicated that he is on the speakers’ bureau of Sanofi-Aventis corporation, is a consultant for Sanofi-Aventis and AstraZeneca, and has received honoraria from Sanofi-Aventis.

Issue
Cleveland Clinic Journal of Medicine - 73(9)
Publications
Topics
Page Number
785-786, 788, 790-792
Sections
Author and Disclosure Information

Paul J. Grant, MD
Clinical instructor, Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

Amir K. Jaffer, MD
Medical director, IMPACT (Internal Medicine Preoperative Assessment Consultation and Treatment) Center; medical director, Anticoagulation Clinic, Section of Hospital Medicine, Cleveland Clinic

Address: Amir K. Jaffer, MD, IMPACT Center, A13, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Jaffer has indicated that he is on the speakers’ bureau of Sanofi-Aventis corporation, is a consultant for Sanofi-Aventis and AstraZeneca, and has received honoraria from Sanofi-Aventis.

Author and Disclosure Information

Paul J. Grant, MD
Clinical instructor, Division of General Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI

Amir K. Jaffer, MD
Medical director, IMPACT (Internal Medicine Preoperative Assessment Consultation and Treatment) Center; medical director, Anticoagulation Clinic, Section of Hospital Medicine, Cleveland Clinic

Address: Amir K. Jaffer, MD, IMPACT Center, A13, Cleveland Clinic, 9500 Euclid Avenue, Cleveland, OH 44195; e-mail [email protected]

Dr. Jaffer has indicated that he is on the speakers’ bureau of Sanofi-Aventis corporation, is a consultant for Sanofi-Aventis and AstraZeneca, and has received honoraria from Sanofi-Aventis.

Article PDF
Article PDF
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Issue
Cleveland Clinic Journal of Medicine - 73(9)
Page Number
785-786, 788, 790-792
Page Number
785-786, 788, 790-792
Publications
Publications
Topics
Article Type
Display Headline
When should prophylactic anticoagulation begin after a hip fracture?
Display Headline
When should prophylactic anticoagulation begin after a hip fracture?
Sections
PURLs Copyright

Disallow All Ads
Alternative CME
Use ProPublica
Article PDF Media

Three-in-One Pill for HIV

Article Type
Changed
Display Headline
Three-in-One Pill for HIV

Article PDF
Author and Disclosure Information

Issue
Federal Practitioner - 23(9)
Publications
Topics
Page Number
35
Legacy Keywords
HIV, AIDS, Atripla, efavirenz, emtricitabine, tenofovir disoproxil fumarate, FDA, Food and Drug Administration, Bristol Myers Squibb, Gilead Sciences, Merck, combination, pill, threeHIV, AIDS, Atripla, efavirenz, emtricitabine, tenofovir disoproxil fumarate, FDA, Food and Drug Administration, Bristol Myers Squibb, Gilead Sciences, Merck, combination, pill, three
Sections
Author and Disclosure Information

Author and Disclosure Information

Article PDF
Article PDF

Issue
Federal Practitioner - 23(9)
Issue
Federal Practitioner - 23(9)
Page Number
35
Page Number
35
Publications
Publications
Topics
Article Type
Display Headline
Three-in-One Pill for HIV
Display Headline
Three-in-One Pill for HIV
Legacy Keywords
HIV, AIDS, Atripla, efavirenz, emtricitabine, tenofovir disoproxil fumarate, FDA, Food and Drug Administration, Bristol Myers Squibb, Gilead Sciences, Merck, combination, pill, threeHIV, AIDS, Atripla, efavirenz, emtricitabine, tenofovir disoproxil fumarate, FDA, Food and Drug Administration, Bristol Myers Squibb, Gilead Sciences, Merck, combination, pill, three
Legacy Keywords
HIV, AIDS, Atripla, efavirenz, emtricitabine, tenofovir disoproxil fumarate, FDA, Food and Drug Administration, Bristol Myers Squibb, Gilead Sciences, Merck, combination, pill, threeHIV, AIDS, Atripla, efavirenz, emtricitabine, tenofovir disoproxil fumarate, FDA, Food and Drug Administration, Bristol Myers Squibb, Gilead Sciences, Merck, combination, pill, three
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

Soft Tissue Augmentation

Article Type
Changed
Display Headline
Soft Tissue Augmentation

Article PDF
Author and Disclosure Information

Hirsch RJ, Cohen JL

Issue
Cutis - 78(3)
Publications
Topics
Page Number
165-172
Sections
Author and Disclosure Information

Hirsch RJ, Cohen JL

Author and Disclosure Information

Hirsch RJ, Cohen JL

Article PDF
Article PDF

Issue
Cutis - 78(3)
Issue
Cutis - 78(3)
Page Number
165-172
Page Number
165-172
Publications
Publications
Topics
Article Type
Display Headline
Soft Tissue Augmentation
Display Headline
Soft Tissue Augmentation
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media

You must justify D&C with fibroid resection

Article Type
Changed
Display Headline
You must justify D&C with fibroid resection

Q I performed a resection of a submucous fibroid and also did uterine curettage. I will report code 58561 (Hysteroscopy, surgical; with removal of leiomyomata) for the primary procedure, but can I also bill for the curettage?

A Yes. Code 58120 (Dilation and curettage, diagnostic and/or therapeutic [nonobstetrical]) is not bundled with code 58561 under the National Correct Coding Initiative (NCCI). But to avoid denial you must establish medical justification for doing the curettage by indicating a diagnosis other than submucous fibroid (218.0).

Article PDF
Author and Disclosure Information

Melanie Witt, RN, CPC-OGS, MA
Independent coding and documentation consultant; former program manager, Department of Coding and Nomenclature, American College of Obstetricians and Gynecologists

Issue
OBG Management - 18(09)
Publications
Topics
Page Number
82-82
Sections
Author and Disclosure Information

Melanie Witt, RN, CPC-OGS, MA
Independent coding and documentation consultant; former program manager, Department of Coding and Nomenclature, American College of Obstetricians and Gynecologists

Author and Disclosure Information

Melanie Witt, RN, CPC-OGS, MA
Independent coding and documentation consultant; former program manager, Department of Coding and Nomenclature, American College of Obstetricians and Gynecologists

Article PDF
Article PDF

Q I performed a resection of a submucous fibroid and also did uterine curettage. I will report code 58561 (Hysteroscopy, surgical; with removal of leiomyomata) for the primary procedure, but can I also bill for the curettage?

A Yes. Code 58120 (Dilation and curettage, diagnostic and/or therapeutic [nonobstetrical]) is not bundled with code 58561 under the National Correct Coding Initiative (NCCI). But to avoid denial you must establish medical justification for doing the curettage by indicating a diagnosis other than submucous fibroid (218.0).

Q I performed a resection of a submucous fibroid and also did uterine curettage. I will report code 58561 (Hysteroscopy, surgical; with removal of leiomyomata) for the primary procedure, but can I also bill for the curettage?

A Yes. Code 58120 (Dilation and curettage, diagnostic and/or therapeutic [nonobstetrical]) is not bundled with code 58561 under the National Correct Coding Initiative (NCCI). But to avoid denial you must establish medical justification for doing the curettage by indicating a diagnosis other than submucous fibroid (218.0).

Issue
OBG Management - 18(09)
Issue
OBG Management - 18(09)
Page Number
82-82
Page Number
82-82
Publications
Publications
Topics
Article Type
Display Headline
You must justify D&C with fibroid resection
Display Headline
You must justify D&C with fibroid resection
Sections
Article Source

PURLs Copyright

Inside the Article

Article PDF Media